GSK’s velzatinib receives Japan orphan designation for GIST

Key highlights
  • Japan’s Ministry of Health, Labour and Welfare granted the designation for gastrointestinal stromal tumour (GIST).
  • Phase III trials are under way in first- and second-line advanced or metastatic GIST.
  • Second-line trial data are expected in the second half of 2027.
  • A Japanese phase II trial, StrateGIST J, is evaluating patients whose disease has progressed or who cannot tolerate available treatments.

Japan designation

Japan’s Ministry of Health, Labour and Welfare granted velzatinib Orphan Drug Designation for gastrointestinal stromal tumour (GIST). The decision was supported by data from the ongoing phase I/Ib StrateGIST 1 trial in advanced GIST. Velzatinib has also received US Fast Track designation and orphan designations in the US and EU.

Development programme

Phase III trials are under way in first- and second-line advanced or metastatic GIST. Enrolment in the second-line trial is ahead of schedule, and data are expected in the second half of 2027. A phase II trial in Japan, StrateGIST J, is evaluating patients whose disease has progressed or who are intolerant to available treatments.

Seven abstracts on velzatinib are scheduled for the Connective Tissue Oncology Society Annual Meeting in Seoul, South Korea, from 18 to 21 November 2026. Topics include clinical analyses by KIT mutation and treatment line, preclinical research on mutation coverage, and translational biomarkers.

Source: GSK

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.